Oct 20 · PIII IMpower110 RCT (n=572) found that atezolizumab resulted in longer overall survival than platinum-based chemotherapy in subgroup of patients with EGFR and ALK wild-type tumours with highest expression of PD-L1 (20.2 vs. 13.1 months; HR death, 0.59; p=0.01) .
Sep 20 · Updated results of PIII IMpower131 study reported at the World Conference of Lung Cancer. Median OS was 14.2 months in arm B (atezolizumab plus chemotherapy; n=343) vs 13.5 months in arm C (chemotherapy alone; n=340), not crossing the boundary for statistical significance (HR=0.88; 95% CI, 0.73-1.05; p=0.16). In the PD-L1–high tumour expression subgroup, median OS was 23.4 vs 10.2 months, respectively (HR=0.48; 95% CI, 0.29-0.81). No new safety signals were observed in this study, but the incidence of grade 3/4 treatment-related adverse events was higher for patients who received atezolizumab vs those who did not (68% vs 57.5%) [12-14].
Sep 19 · Roche announce PIII IMpower 110 (NCT02409342) study (n=555) met primary endpoint in interim analysis, demonstrating statistically significant OS benefit in people with high PD-L1 expression (TC3/IC3-WT) vs. chemotherapy alone .
Jan 19 · Interim OS data has been presented at ESMO 2018 .
Jun 18 · Roche announce further data from PIII IMpower131 study (n=1,021). At 12 months, median PFS in patients on atezolizumab monotherapy was 6.3 months vs 5.6 months in the chemotherapy group .
Mar 18 · Phase III clinical trial, IMpower131, of Tecentriq (atezolizumab) with carboplatin and Abraxane met its co-primary endpoint of PFS in squamous NSCLC. Although a statistically significant OS benefit wasn’t seen, the study will continue.
Mar 17 · Recruitment complete in the PIII IMpower131 study involving 1,025 patients with squamous NSCLC. Patients have been randomised to first-line treatment in one of the 3 arms: Arm A atezolizumab plus paclitaxel + carboplatin; Arm B atezolizumab plus nab-paclitaxel + carboplatin; Arm C nab-paclitaxel + carboplatin. PFS & OS will be assessed .
Jul 16 · PIII IMpower 110 (NCT02409342) study (n=400) is currently recruiting PDL1-selected pts with squamous or non-squamous NSCLC from sites globally (including the UK). Primary outcome data collection is expected to complete Apr 2018. PIII IMpower 111 is to be consolidated into IMpower 110. IMpower 111 began in Q2 15 and is recruiting 400 PDL1-selected patients with squamous NSCLC and comparing atezolizumab monotherapy with gemcitabine plus cisplatin or carboplatin .
Dec 15 · companion diagnostic test also in development and will be required to identify suitable patients .
Jun 15 · PIII IMpower 111 (NCT02409355) study (n=400) is designed to evaluate and compare safety and efficacy of atezolizumab (MPDL3280A) compared with treatment with gemcitabine + cisplatin or carboplatin in patients with chemotherapy-naive, Stage IV squamous NSCLC. Study sites include the US & EU (inc. UK). Collection of PFS primary outcome data should complete Jul 19 .
Jun 15 · Roche announce patient enrolment begins in two PIII studies. In one, 1,200 pts will be recruited to assess the effects of RG7446 with nab-paclitaxel or paclitaxel and carboplatin vs. chemotherapy alone on progression-free survival. The second study will recruit 400 PD-L1-selected pts and compare RG7446 monotherapy vs. chemotherapy (gemcitabine + carboplatin/cisplatin) .